Balchem Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Balchem Corporation on September 12, 2019. The filing reports corporate governance changes effective as of the filing date, specifically regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Board Election: The Board elected Joyce Lee to fill a vacancy. She will serve as a Class 2 Director and stand for election at the 2021 Annual Meeting of Shareholders.
- Director Background: Ms. Lee is currently the president of North America for Bayer Animal Health. Previously, she served as Executive Vice President and Area President of Canada and Latin America at Zoetis Inc. (2013-2017) and held senior leadership roles at Pfizer.
- Committee Assignment: Ms. Lee will serve on the Audit Committee and is eligible for director compensation programs.
- Bylaw Amendments: The Board amended the Bylaws to increase the total number of Board members from seven to eight and the number of Class 2 Directors from two to three.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. No arrangement or understanding exists between Ms. Lee and any other person regarding her selection as a director.
Key Facts for Investor Verification
- Confirmation of Joyce Lee's appointment to the Board and the Audit Committee.
- Verification of the Bylaw amendment increasing Board size to eight members.
- Review of Ms. Lee's independence and potential conflicts of interest given her current role at Bayer Animal Health.
- Confirmation that Ms. Lee will stand for shareholder election in 2021.